Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

111, Inc. (YI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7500-0.2300 (-7.72%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • A
    Aleksandr
    The good news, bit by bit, will break through this slab of uncertainties that Chinese regulators have created. New rules in health care will establish order. Unscrupulous will be removed from the game. I assume that the market consolidation will continue due to retired players. 111 inc margins will continue to grow by doubling the scale achieved in 2021. The dynamics of indicators in percentage confirms their words about the imminent exit to profit. According to various forecasts, the market for prescription drugs will grow faster than the market for over-the-counter drugs. This is the picture all investors would like to see. Now it is sold at the price of a canvas))). Let's see what they draw. https://en.pingwest.com/a/9685
  • H
    Harold
    huge revenue growth, but what does it actually mean if their gross margin is stuck below 5% and they're burning $25m every quarter? they have $235m in cash and receivables but $235m in payables + $17m in current debt and $68m in current accrued expenses. with such razor thin gross margins and negative net margins still (it has improved in the last 5 years) if anything happens to their revenue stream they will go underwater in a matter of months. this does not seem as safe as people make it out to be, in my opinion
    Neutral
  • P
    Peter
    Investors are rotating from US tech to Chinese tech. JD up 11% YTD, BIDU up 10%.
    Not so for YI which is down 9% YTD.
    I am not bashing, just very disappointed in the Board and management of what could be a very promising company in a very promising field. Investors have spoken: Company valuation is a complete joke - barely above cash in bank. Hope something will be done soon.....
  • A
    Aleksandr
    Hello everyone! The boat called at the southern port. Congratulations to new passengers on a successful purchase of cheap tickets. Hopefully now we will irrevocably go north. I wish you all good luck and patience on your trip. The tailwind should get stronger, because this is a boat that will bring two billion dollars in revenue in 2021.
  • A
    Adea
    Hello what's the best way to get a legit trade cos I've been making my personal research for a while now
  • A
    Aleksandr
    A very volatile stock. There is a lot of fear that this business is threatened by regulation. It seems to me that this platform can play a significant role in the efforts of the Chinese government to reduce the cost of health care. Are there any shareholders living in China? Please share local information.
  • A
    Aleksandr
    According to the report, the value of assets is 485 million. Now capitalization is below the value of assets.
  • J
    Jimmy
    Please somebody suggest me what to do. I am already losing 1600$. I have 188 @ 12.36$
  • S
    Sam
    This was interesting , any thoughts ?
  • P
    Peter
    Why is this stock trading at such a low level despite the fast growth?
    The other Chinese tech companies seem to be recovering some of their losses. It can not just be because of the 111 Inc founders dominant voting rights.
    I noticed that their accounts payable are now up to USD 240 million! This seems very high. Can this be true or is it some kind of loan?
  • T
    Terry
    Am I missing something?

    111 (NASDAQ:YI) is a leader in the online pharmacy industry in China. It partners with local drugstores to deliver a wide array of products to the consumer's doorstep, among them prescription pharmaceuticals, Chinese medicines, nutritional supplements, medical devices, contact lenses, beauty items, and reproductive products.
    Management is nearing its goal of extending its reach to more than 300,000 pharmacies in China -- 57% of the country's total, serving more than 1 billion people. The prescription medicine market in China amounts to 300 billion yuan (approximately $46 billion) annually.
    Since its IPO in 2018, 111 has delivered eight consecutive quarters of growth. Back in Q3 2020, its revenue increased by a stunning 113% year over year to 2.363 billion yuan (about $366 million). At the same time, its non-GAAP net loss narrowed to just 4% of its revenue, compared to 10% in Q3 2019. 111 also expanded its order count by 297% to 1.14 million and doubled its number of partnerships with pharmaceutical companies to 301.
    The sky is the limit for 111. The company intends to offer new branded medications on its platform. This is significant as many Chinese consumers could previously only afford cheap generic variants. It also has plans to offer products that would target chronic illnesses such as diabetes.
    For all its growth and potential, you may be surprised to learn that the company is trading at just 2 times sales.

    How is this sooo cheap considering the huge growth and such a low!? I know people are cautious about Chinese companies but is that the only reason?
    Bullish
  • E
    Eric
    Even after today:
    This is a $1.5B company doing +$1B in sales...
    Growing at 100% recently...
    Expanding meaningfully into Telehealth...
    In the fastest growing economy in the world...
    Focused on the most underserved parts of that economy (second tier cities...each one about the size of an LA or NYC, btw)...

    Looking forward to next ER
  • E
    Eric
    NASDAQ article on YI today... top 4 health companies to buy now
  • A
    Aleksandr
    Hello everyone! Compare its Q2 results to TDOC. Now take a close look at the stock price. I thought it was not possible! Fantastic opportunity to buy!
  • d
    dave
    2018 Net revenues were RMB655.6 million (US$97.7 million), representing an increase of 98.5% year-over-year? So this is valued at only 3.5x multiple of revenue? Most Tech startups are valued much much higher. @YI #YI
    Bullish
  • E
    Eric
    The float on YI is only about 24M shares - a quarter of that sold just today, probably about half this week

    This is a pretty solid base at these price levels ...with good reason, YI is still very reasonably valued when comparing the revenue, market cap, and addressable market to other telehealth companies
    Bullish
  • T
    Terry
    Hedge funds seem to be snapping this up after hours and then it goes back down during normal market hours... earnings around the corner will be interesting
    Bullish
  • E
    Eric
    TDOC just reported growth of +100%, annualized revenue of ~$1.5B...after hours dropped to a market cap of $36B
    YI annualized revenues are ~$1B and market cap is less than $2B

    Looking forward to next earnings - YI serves a market 4x the size of TDOC...share price could be $200/sh and they’d still only be half the size of TDOC on the same revenue stream
    Bullish
  • N
    NHJ
    This company is so massively undervalued, it is grotesque. Yes, low net margins are a concern but given that 111 is still investing in its platform and logistics, understandable.
    As soon as 111 posts a profit, the shares should SKY ROCKET to at least $270 where it's fair value already lies right now, according to my DCF calculations. Great time to accumulate imo.
    Bullish
Advertisement
Advertisement